Pfizer Inc. (NYSE:PFE) Shares Sold by Denver Wealth Management Inc.

Posted by Defense World Staff on Apr 10th, 2023

Denver Wealth Management Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 5.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,984 shares of the biopharmaceutical company’s stock after selling 772 shares during the period. Denver Wealth Management Inc.’s holdings in Pfizer were worth $665,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Lam Group Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $25,000. Karp Capital Management Corp acquired a new stake in Pfizer during the third quarter worth about $27,000. Worth Asset Management LLC bought a new position in Pfizer in the first quarter worth about $29,000. My Personal CFO LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $32,000. Finally, Delos Wealth Advisors LLC grew its holdings in shares of Pfizer by 100.0% during the third quarter. Delos Wealth Advisors LLC now owns 800 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 400 shares during the last quarter. Institutional investors own 67.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PFE. Credit Suisse Group reduced their price objective on Pfizer from $54.00 to $50.00 and set an “outperform” rating for the company in a research report on Wednesday, February 1st. Wells Fargo & Company dropped their price objective on shares of Pfizer from $50.00 to $44.00 and set an “equal weight” rating on the stock in a report on Friday, March 17th. Morgan Stanley decreased their target price on shares of Pfizer from $53.00 to $45.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 1st. Atlantic Securities cut their price target on Pfizer from $50.00 to $46.00 and set a “neutral” rating on the stock in a report on Wednesday, February 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $75.00 price target on shares of Pfizer in a research report on Wednesday, February 1st. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $49.93.

Pfizer Price Performance

NYSE PFE opened at $41.50 on Monday. Pfizer Inc. has a 1 year low of $39.23 and a 1 year high of $56.32. The business’s fifty day moving average is $41.66 and its two-hundred day moving average is $45.47. The stock has a market capitalization of $234.24 billion, a P/E ratio of 7.57, a P/E/G ratio of 1.40 and a beta of 0.64. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.00 and a current ratio of 1.22.

Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, beating the consensus estimate of $1.03 by $0.11. The business had revenue of $24.30 billion during the quarter, compared to the consensus estimate of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. Pfizer’s revenue was up 1.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.08 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.

Insider Transactions at Pfizer

In other news, major shareholder Pfizer Inc purchased 1,811,594 shares of Pfizer stock in a transaction that occurred on Friday, March 17th. The stock was acquired at an average price of $2.76 per share, for a total transaction of $4,999,999.44. Following the transaction, the insider now owns 5,952,263 shares in the company, valued at $16,428,245.88. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is currently owned by insiders.

Pfizer Company Profile

(Get Rating)

Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.